Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like New precision medicine approach helps detect subgroups of people with obesity at high risk of diabetes and heart disease October 25, 2024 Altered gait contributes to long-term knee problems after ACL surgery December 4, 2024 The global quest for the right balance of sodium and potassium in the diet April 9, 2024
New precision medicine approach helps detect subgroups of people with obesity at high risk of diabetes and heart disease October 25, 2024